The unfolding COVID-19 pandemic has seen an unprecedented sharing of information to support clinicians in making clinical decisions at the coal-face.  But has this pressure to publish data come at the cost of lower standards of governance?

Colin McArthur, co-lead of the ANZ arm of the REMAP-CAP study joins Todd on the podcast to discuss the trials and tribulations of hydroxychloroquine, and THAT observational study.

See omnystudio.com/listener for privacy information.